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Winston-Salem, North CarolinaOBJECTIVES The aim of this study was to determine the effect of stress cardiac magnetic resonance
(CMR) imaging in an observation unit (OU) on revascularization, hospital readmission, and recurrent
cardiac testing in intermediate-risk patients with possible acute coronary syndromes (ACS).
BACKGROUND Intermediate-risk patients commonly undergo hospital admission with high rates of
coronary revascularization. It is unknown whether OU-based care with CMR is a more efﬁcient alternative.
METHODS A total of 105 intermediate-risk participants with symptoms of ACS but without deﬁnite
ACS on the basis of the ﬁrst electrocardiogram and troponin were randomized to usual care provided by
cardiologists and internists (n ¼ 53) or to OU care with stress CMR (n ¼ 52). The primary composite
endpoint of coronary artery revascularization, hospital readmission, and recurrent cardiac testing at 90
days was determined. The secondary endpoint was length of stay from randomization to index visit
discharge; safety was measured as ACS after discharge.
RESULTS Themedian age of participantswas 56 years (range 35 to 91 years), 54%weremen, and 20%had
pre-existing coronary disease. Index hospital admission was avoided in 85% of the OU CMR participants. The
primaryoutcomeoccurred in20usual careparticipants (38%) versus 7OUCMRparticipants (13%) (hazard ratio:
3.4; 95% conﬁdence interval: 1.4 to 8.0, p¼ 0.006). The OUCMR group experienced signiﬁcant reductions in all
components: revascularizations (15% vs. 2%, p ¼ 0.03), hospital readmissions (23% vs. 8%, p ¼ 0.03), and
recurrent cardiac testing (17% vs. 4%, p ¼ 0.03). Median length of stay was 26 h (interquartile range: 23 to
45 h) in the usual care group and 21 h (interquartile range: 15 to 25 h) in the OU CMR group (p < 0.001).
ACS after discharge occurred in 3 usual care participants (6%) and no OU CMR participants.
CONCLUSIONS In this single-center trial, management of intermediate-risk patients with possible
ACS in an OU with stress CMR reduced coronary artery revascularization, hospital readmissions, and
recurrent cardiac testing, without an increase in post-discharge ACS at 90 days. (Randomized
Investigation of Chest Pain Diagnostic Strategies; NCT01035047) (J Am Coll Cardiol Img 2013;6:785–94)
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786ecent reports have demonstrated the adapt-
ability of cardiac magnetic resonance (CMR)
for testing emergency department (ED) pa-
tients with symptoms concerning for acute
coronary syndromes (ACS) (1–5). Attributes of
CMR making this modality appealing for use in ED
patients are its abilities to diagnose myocardial
infarction (MI) before troponin elevation (1),
differentiate between new and old infarcts (6), and
accurately determine prognosis (7). These strengths
of CMR allow patients at intermediate risk for
ACS, commonly managed as inpatients, to be
evaluated in an observation unit (OU) setting.
In intermediate-risk patients, OU-based care
with stress CMR testing reduced cost over the
course of 1 year compared with an inpatient care
strategy in a recent analysis of a single-center ran-
domized trial (8). An ancillary ﬁnding of that trial
was a reduction in coronary revascularization asso-
ciated with OU CMR that did not reach statistical
signiﬁcance. Reducing revascularization proceduresromes
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Manuscript rmay be desirable because they are expen-
sive, and up to two-thirds of coronary
revascularization procedures in the United
States are of uncertain appropriateness or
do not meet appropriateness criteria (9). In
addition, emerging evidence suggests that
intervention in stable coronary lesions may
not improve outcomes (10), and revascu-
larization is associated with a high rate of
readmissions and repeat revascularizations
in the short term after the procedure (11).
Together, these data suggest that efﬁ-ciency gains could result from more carefully
selecting patients for coronary revascularization
procedures.
Evaluation of the efﬁciency of a cardiac-related
care pathway must consider not only coronary
revascularization but also the impact on other
clinical events, such as the need for additional car-
diac testing, hospital readmissions, and delayed
cardiac events. We hypothesized that an OU CMR
care strategy would provide a highly accurate,
noninvasive, comprehensive assessment during theedicine, Winston-Salem, North Carolina; and the #Departmen
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eceived August 21, 2012; accepted November 1, 2012.index visit, thereby allowing some patients to safely
avoid revascularization while reducing hospital
readmissions and recurrent cardiac testing. Ac-
cordingly, we conducted a single-center trial powered
to detect a difference in the composite endpoint of
coronary revascularization, hospital readmission, and
recurrent cardiac testing 90 days after randomiza-
tion between OU CMR and usual inpatient care
strategies.
METHODS
Study design. We conducted a randomized,
controlled, single-center clinical trial funded by
grant 1 R21 HL097131-01A1 from the National
Heart, Lung, and Blood Institute. The study was
approved by the institutional review board of the
Wake Forest School of Medicine and registered at
ClinicalTrials.gov (NCT01035047) before enroll-
ment. All participants provided written consent for
study participation and were randomized to an
OU CMR strategy or usual care, an inpatient-based
strategy. In the OU CMR strategy, participants
were managed in an OU setting, underwent serial
troponin measurements at 4 and 8 h after arrival,
and underwent stress CMR exams at the ﬁrst
available time. Participants in the usual care group
were evaluated by the inpatient service for hospital
admission and further diagnostic evaluation as
determined by their care providers. Disposition
decisions and subsequent testing in both groups
were performed at the discretion of the care
providers.
Setting. Participants were recruited from the ED of
Wake Forest Baptist Medical Center. The study
institution is a tertiary care academic medical center
located in the Piedmont Triad area of North
Carolina, serving urban, suburban, and rural
populations. The ED volume in 2011 consisted of
103,000 patient encounters. This study population
is distinct from other studies we have previously
published from the OU setting.
At the study institution, patients with chest
pain and related symptoms, but without deﬁnitet of Radiology, Wake Forest School of Medicine, Winston-
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787ACS, are risk-stratiﬁed by attending emergency
physicians in the ED as low risk (TIMI [Throm-
bolysis In Myocardial Infarction] risk score < 2) or
elevated risk. Low-risk patients are managed in the
OU, whereas elevated-risk patients are managed as
inpatients. Cardiac imaging modalities available in
the OU and inpatient settings include stress imag-
ing with echocardiography, nuclear imaging, and
CMR; coronary computed tomographic angiog-
raphy; and invasive catheter coronary angiography.
The OU is staffed by midlevel providers, and
oversight is provided by attending emergency phy-
sicians. These care providers have been exposed to
the clinical use of CMR imaging since 2008 and
have managed intermediate-risk participants with
CMR imaging in previous trials (4,8).
Participants. Patients at least 21 years old presenting
with symptoms suggestive ofACSwere screened, and
those eligible were consecutively approached during
enrollment hours (6 days excluding Saturday, 80 h/
week). Eligibility criteria required an inpatient orOU
evaluation of the patient’s symptoms because of at
least intermediate-risk chest pain, deﬁned as either
TIMI risk score (12) $ 2 (corresponding to 10% or
greater risk for ACS at 30 days in patients with un-
differentiated chest pain [13]) or a physician’s global
risk assessment based on the American College of
Cardiology and American Heart Association guide-
lines (14) of intermediate or high risk. Additionally,
at the time of enrollment, theEDattending physician
had to declare the patient as being safe for OU care
and that the patient could be discharged home if
cardiac disease were excluded as the cause of
symptoms. Patients were determined ineligible for
the following reasons: deﬁnite ACS at the time of
enrollment (elevated initial troponin, new ST-
segment elevation [$1 mm] or depression
[$2 mm]), known inducible ischemia, hypoten-
sion, contraindications to CMR, life expectancy
<3 months, pregnancy, coronary revascularization
within 6 months, and increased risk for nephrogenic
systemic ﬁbrosis (deﬁned in the study as creatinine
clearance<45ml/min or<60ml/min if concomitant
chronic liver disease, clinical concern for acute kidney
injury, hepatorenal syndrome, or solid organ
transplantation).
Randomization. After obtaining written consent,
participants were stratiﬁed on the basis of the
presence of known coronary disease ($50% stenosis,
prior MI, or revascularization), and assigned within
strata to 1 of the 2 treatment arms with equal
probability using variably sized permuted block
randomization. The randomization sequence was
generated using nQuery Advisor 6.0 (StatisticalSolutions, Saugus, Massachusetts) and integrated
into a secure Web site that was used by the study
coordinators to register participants and obtain the
study group assignments. The clinical investigators
and staff members were blinded to the randomiza-
tion sequence.
Study procedures. After randomization, usual care
participants underwent consultation in the ED by
the admitting service in accordance with customary
practice. Care delivery in this group was not directed
by the study protocol. In the OU CMR group,
orders were placed for serial troponin and electro-
cardiographic assessments at 4 and 8 h after the
initial evaluation, for placement into observation
status, and for a vasodilator CMR exam to be
conducted at the ﬁrst available time. CMR exams
were integrated into the daily caseload of exams
without special scheduling provisions for this study.
Clinical reports from the CMR exams were inter-
preted by the care providers in the OU to make a
decision to discharge the patient home or obtain a
cardiology consultation. Interpretations, the need
for cardiology consultation, and decisions to
perform revascularization were not directed by the
study protocol.
CMR imaging. Participants underwent CMR
imaging in accordance with imaging protocols used
in previous trials and for clinical care at the study
site that have been previously described in detail
(4,5). Imaging was performed using a 1.5-T
Siemens Magnetom Avanto system (Siemens
Healthcare, Erlangen, Germany). An initial order
was placed for an adenosine vasodilator stress exam,
with regadenoson and dobutamine available as
alternatives. Participants underwent assessments of
resting wall motion, T2 imaging for edema, stress
perfusion, rest perfusion, and delayed enhancement.
Images were interpreted by a reading pool of board-
certiﬁed cardiology and radiology faculty members
with at least level 2 training in CMR (15), with
results entered into the electronic medical record.
Blinding. Per protocol, inpatient care providers in
the usual care group were not informed of the
subject’s participation. Subjects were also asked to
refrain from discussing their participation in a
clinical trial with inpatient clinical staff members.
Because care providers in the OU CMR group were
integral to delivering the care pathway, these
providers could not be blinded to the study
intervention. Participants in both groups were not
routinely made aware of the study endpoints during
the consent or follow-up process.
Data collection and processing. The study was
conducted in accordance with standards of good
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788clinical practice, standardized reporting guidelines
(16), and key data elements and deﬁnitions (17). A
detailed map of sources of data was created before
study initiation. Medical records were used as the
source for data elements reliably contained in the
medical record. Data collection templates were
implemented to prospectively collect data from
patients and ED care providers that were not
reliable or not present in the electronic medical
record. Data were recorded in Web-based case
report forms and transferred to a secure Structured
Query Language relational database.
Follow-up was conducted during the index visit
using a structured record review. At both 30 and
90 days, a structured record review was followed by
a structured telephone interview. Outcome events
reported at other health care facilities were
conﬁrmed using a structured review of those
medical records. Incomplete telephone follow-up
at 90 days was handled using the following algo-
rithm: participants with ongoing visits in theFigure 1. CONSORT Diagram
The study randomized 105 participants to observation unit (OU) cardiac m
were analyzed on the basis of intent to treat. CONSORT ¼ Consolidateelectronic medical record were considered to have
complete information and were classiﬁed on the
basis of the data available in the medical record;
participants with no ongoing visits were consid-
ered lost to follow-up at the point of last contact
(index visit discharge or 30-day telephone inter-
view) and were censored in the analysis. Separate
analyses were conducted assuming that those
participants with no telephone contact had no
events, as evidenced by their lack of events on
chart review.
Outcomes. The primary outcome was a composite
of coronary revascularization, all-cause hospital
readmission, and recurrent cardiac testing within
90 days of randomization. Coronary revasculariza-
tion included percutaneous and surgical revascular-
ization occurring any time after randomization.
Hospital readmission was deﬁned as an overnight
stay or placement into observation or inpatient
status for >8 h, for all causes, after the index visit.
Recurrent cardiac testing was deﬁned as receivingagnetic resonance (CMR) imaging (n ¼ 52) or usual care (n ¼ 53). All
d Standards of Reporting Trials; ED ¼ emergency department.
Table 1. Participant Demographics and Medical Histories
Usual Care
(n [ 53)
OU CMR
(n [ 52)
Age, yrs 59 (40–76) 54 (35–91)
Age $65 yrs 15 (28) 9 (17)
Men 29 (55) 28 (54)
Race/ethnicity
Hispanic 1 (2) 1 (2)
Black 15 (28) 20 (38)
White 37 (70) 29 (56)
Other 0 (0) 2 (4)
BMI, kg/m2 29.6 (19.7–46.8) 30.7 (16.4–51.2)
Underweight 0 (0) 1 (2)
Normal 13 (25) 12 (23)
Overweight 16 (30) 10 (19)
Obese 24 (45) 29 (56)
Hypertension 45 (85) 37 (71)
Diabetes mellitus 16 (30) 16 (31)
Current smoking 20 (38) 21 (40)
Hyperlipidemia 39 (74) 33 (63)
Prior heart failure 1 (2) 3 (6)
Prior MI 7 (13) 9 (17)
Prior PCI 9 (17) 7 (13)
Prior CABG 1 (2) 0 (0)
Values are median (range) or n (%).
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CMR ¼ car-
diac magnetic resonance; MI ¼ myocardial infarction; OU ¼ observation unit;
PCI ¼ percutaneous coronary intervention.
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7891 or more of the following procedures after index
visit discharge: cardiac echocardiography, CMR,
nuclear imaging, coronary computed tomographic
angiography, or invasive angiography.
The secondary outcome was index visit length of
stay, deﬁned as the time elapsed between random-
ization and discharge from the facility. Safety events
were all-cause mortality within 90 days, adverse
events related to index visit stress testing, and ACS
after discharge and within 90 days of randomiza-
tion, deﬁned as 1 of the following: 1) acute MI
according to the universal deﬁnition (18);
2) ischemic symptoms leading to revascularization;
3) death likely related to cardiac ischemia; and
4) discharge diagnosis of unstable angina with evi-
dence of >70% coronary stenosis or inducible
ischemia on stress testing if coronary angiography
was not performed.
Sample size. A 3-stage, group sequential design
was used to assess the difference in event rates of
the primary outcome between the 2 groups. We
calculated that 27 events were needed to provide
80% power for detecting a hazard ratio of 3.0 at
the 5% 2-sided level of signiﬁcance when data
are analyzed 3 times according to the O’Brien-
Fleming stopping rules (19) (Sþ SeqTrial,
TIBCO Spotﬁre, Somerville, Massachusetts). The
anticipated effect size was based on preliminary
data from another trial (8) demonstrating 28%
versus 9% event rates (hazard ratio: 3.5) for the
primary outcome favoring OU CMR. We antici-
pated that approximately 146 patients would be
needed to achieve the required 27 events, on the
basis of the estimate of the fraction of patients
experiencing events.
Data analysis. For the primary outcome, the time to
the composite outcome was the minimal time to any
of the component events. Kaplan-Meier methods
were used to estimate the time-to-event distribu-
tions for the 2 groups. Participants lost to follow-up
were considered censored at their last contacts. The
primary test for the group effect was accomplished
using a Cox proportional hazards regression model
for the time to the composite event. The primary
model was based on intent to treat and included the
assignment group and the stratiﬁcation factor as
covariates. The results of this analysis were
compared with the O’Brien-Fleming stopping
boundaries (19) during 2 interim analyses and the
ﬁnal analysis. At the ﬁnal analysis, the null
hypothesis was rejected if the p value was <0.045.
Length of stay was measured as a continuous
variable from the time of ED presentation to the
time of hospital discharge. All participants weredischarged; there were no index visit deaths. A
Kruskal-Wallis test was used to assess the group
difference in length of stay. Data analysis was con-
ducted using SAS version 9.2 and SAS Enterprise
Guide version 4.3 (SAS Institute Inc., Cary, North
Carolina).
RESULTS
Over 67 weeks, 4,996 patients presented during
the hours of screening and had either a chief
symptom of chest pain or troponin plus electro-
cardiography ordered. Of these with available
information, the median age was 56 years, 48%
were men, and 24% had prior coronary disease.
From this population, 270 patients were
approached, and 105 consented and were enrolled
(Fig. 1). After randomizing 105 subjects (53
inpatients, 52 OU CMR patients), the target
number of participants with events (n ¼ 27) was
observed. No participants were removed from the
study cohort after randomization, and analysis was
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790performed on the basis of intent to treat. Follow-
up was conducted via chart review in all partici-
pants, and all but 6 completed the telephone
interview for 90-day events (Fig. 1). To under-
stand the likelihood of undetected events among
these 6 participants, the proportion of participants
experiencing events not referenced in the medical
records of the study institution was calculated. In
total, 26 of 27 participants (96%) with events had
evidence of the events in the records of the study
institution. The remaining event was conﬁrmed
by obtaining medical records from another
institution.Table 2. Presenting Characteristics and Physical Exam Findings
Usu
Presenting characteristics
Chest pain chief symptom* 47
Chest pain at rest* 43
Multiple episodes of symptoms within 24 hy 30
Chest pain present on arrival to the EDy 34
Chest pain pleuritic* 3
Physical exam
Heart rate, beats/minz 78
Systolic blood pressure, mm Hgz 14
Diastolic blood pressure, mm Hgz 87
Rales* 0
Chest pain reproducible* 4
Overall ECG classiﬁcation*
Normal 34
Nonspeciﬁc changes 12
Early repolarization only 0
Abnormal but not diagnostic of ischemia 3
Infarction or ischemia known to be old 1
Infarction or ischemia not known to be old 3
Suggestive of acute MI 0
Risk stratiﬁcation
ED physician assessment of % likelihood of
ACS within 30 daysx
5
TIMI risk scorek
0 1
1 8
2 21
3 19
4 3
5 1
Values are n/N (%), mean  SD, or median (interquartile range). *Fisher exact test.
Kruskal-Wallis tests. kKruskal-Wallis test.
ACS ¼ acute coronary syndromes; ECG ¼ electrocardiographic; ED ¼ emergency de
Table 1.The study cohort had a median age of 56 years
(range 35 to 91 years), 54% were men, 30% had
histories of diabetesmellitus, and 20%were known to
have pre-existing coronary artery disease (Table 1).
Chest pain was the chief symptom in 91% of par-
ticipants, 89% had pain at rest, 65% had numerous
episodes within 24 h, and 60% had normal electro-
cardiographic ﬁndings at presentation (Table 2). The
TIMI risk score measured near the time of
randomization did not differ among study groups
and was most commonly 2 or 3 (range 0 to 5).
In subjects randomized to usual care, the dispo-
sition from the ED was inpatient admission for 46al Care OU CMR p Value
/50 (94) 46/52 (88) 0.488
/50 (86) 48/52 (92) 0.353
/49 (61) 29/52 (56) 0.578
/50 (68) 32/52 (62) 0.495
/50 (6) 6/52 (12) 0.488
 12 78  16 0.946
9  21 146  21 0.570
 12 82  14 0.058
/50 (0) 1/52 (2) 1.000
/47 (9) 5/47 (11) 1.000
0.213
/53 (64) 29/52 (56)
/53 (23) 8/52 (15)
/53 (0) 1/52 (2)
/53 (6) 6/52 (12)
/53 (2) 6/52 (12)
/53 (6) 2/52 (4)
/53 (0) 0/52 (0)
(5–10) 5 (5–10) 0.852
0.873
/53 (2) 1/52 (2)
/53 (15) 2/52 (4)
/53 (40) 29/52 (56)
/53 (36) 17/52 (33)
/53 (6) 2/52 (4)
/53 (2) 1/52 (2)
yChi-square test. zData were analyzed using t tests. xData were analyzed using
partment; TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in
Table 3. Cardiac Testing and Disposition During the Index Hospital Visit
Usual Care
(n [ 53)
OU CMR
(n [ 52) p Value
First cardiac test completed d
None 5 (9) 0 (0)
Stress CMR 3 (6) 50 (96)
Stress echocardiography 33 (62) 2 (4)
Resting echocardiography 3 (6) 0 (0)
Stress nuclear imaging 0 (0) 0 (0)
Cardiac catheterization 8 (15) 0 (0)
Coronary computed tomographic
angiography
1 (2) 0 (0)
Elapsed time: ED arrival to ﬁrst cardiac
imaging test completed (h)*
22.3 (18.7–25.8) 20.9 (15.7–23.4) 0.028
Hospital admission from ED or
observation unit
47 (89) 8 (15) d
Values are n (%) or median (interquartile range). *Data were analyzed using Kruskal-Wallis tests.
Abbreviations as in Tables 1 and 2.
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791patients (87%), discharge for 3 (6%), OU for 3 (6%),
and leaving against medical advice for 1 (2%). In
the OU CMR group, all subjects were placed in the
OU, of whom 44 (85%) were discharged home; the
remaining 8 participants (15%) were admitted.
Median length of stay from randomization to ﬁnal
discharge from the hospital was 26 h (interquartile
range [IQR]: 23 to 45 h) in the usual care group and
21 h (IQR: 15 to 25 h) in the OU CMR group
(p < 0.001).
Cardiac imaging or angiography during the in-
dex visit was performed in 48 of 53 usual care
participants (91%) and all OU-CMR participants.
In the usual care group, the ﬁrst test modalities
were stress echocardiography in 33 (62%), cathe-
terization in 8 (15%), stress CMR in 3 (6%),
resting echocardiography in 3 (6%), coronary
computed tomographic angiography in 1 (2%), and
no testing in 5 (9%). Median time to completion
of testing in the usual care group was 22 h (IQR:
19 to 26 h). The ﬁrst cardiac test in the OU CMR
group was CMR in 50 (96%) and stress echocar-
diography in 2 (4%) participants (Table 3). Median
time to completion of the ﬁrst test was 21 h (IQR:
16 to 23 h).
During the index visit, elevated troponin levels
occurred in 8 participants (5 usual care and 3 OU
CMR participants) after randomization and before
invasive angiography (Table 4). On cardiac imag-
ing, 6 OU-CMR participants (12%) had acute or
inducible ischemia, all detected with vasodilator
stress CMR, leading to invasive angiography in
5 and revascularization in 1; 2 had abnormal
delayed enhancement, 1 from an acute MI and 1
from a prior MI. In the usual care group, 11 par-
ticipants (21%) underwent invasive angiography
during the index visit, leading to revascularization
in 7 (13%).
The primary outcome composite at 90 days
occurred in 20 participants (38%) in the usual care
group and 7 (13%) in the OU CMR group
(Table 5). In the Cox proportional hazards model,
usual care was associated with a hazard ratio
of 3.4 (95% conﬁdence interval: 1.4 to 8.0, p ¼
0.006). In inpatient versus OU CMR participants,
cardiac testing after discharge occurred in 9 (17%)
versus 2 (4%) participants (p ¼ 0.03), revascular-
ization after randomization in 8 (15%) versus 1
(2%) participant (p ¼ 0.03), and rehospitalization
in 12 (23%) versus 4 (8%) participants (p ¼ 0.03).
Three protocol-deﬁned safety events occurred, all
due to ACS after discharge among usual care
subjects.DISCUSS ION
We found that the OU CMR care pathway in
elevated-risk participants is an efﬁcient alternative to
inpatient care and can shorten hospital length of
stay and reduce revascularization, recurrent cardiac
testing, and hospital readmissions, in agreement
with trends observed in a prior trial (5,8). Partici-
pants in this trial were consistent with intermediate-
risk patients enrolled in other trials in terms of age,
prior cardiac event rates (Table 1) (5,20), and TIMI
risk score (Table 2). Reﬂective of typical care
delivered to these patients across the United States,
the usual care group underwent a wide variety of
initial testing modalities, most commonly stress
echocardiography (51%) and cardiac catheterization
(17%) (Table 3). In this context, an OU CMR
pathway whereby nearly all participants underwent
stress CMR as the ﬁrst objective cardiac test appears
to improve efﬁciency and did not incur any safety
events through 90 days (Tables 3 and 4, Fig. 2).
Assessing the net clinical beneﬁt of reducing
revascularizations is complicated. Appropriateness
criteria for coronary revascularization are intricate
and vary on the basis of an individual patient’s
clinical data, including angina severity and results
from biomarker, invasive, and noninvasive tests
(21). Because all patients cannot receive all possible
tests before revascularization, these decisions are
made on the basis of available data. The ﬁndings
from this trial suggest that the order in which tests
are conducted, and perhaps the location of care
delivery, inﬂuences decisions regarding the need for
Table 4. Participants With Troponin Levels Higher Than the Upper Limit of Normal or Undergoing Revascularization During the Index Visit
Age
(yrs) Sex Group
Peak Troponin Before Cath
(ng/ml)
Peak Troponin
(ng/ml) First Test
Target
Vessel(s)
Maximal Target
Vessel Stenosis Notes
47 Male OU CMR d 0.06 CMR d d
48 Male OU CMR 1.99 214.30 CMR Ramus 100 PCI
48 Female OU CMR d 0.41 CMR d d d
40 Male UC 0.14 56.90 Cath RCA 20 RCA dissection during cath
58 Male UC 0.00 0.06 CMR Graft vessel 90 PCI
61 Female UC 0.13 0.13 Cath Distal RCA 90 PCI
61 Male UC 0.02 0.14 Cath Mid LAD and prox circ 80 and 98 PCI
63 Male UC 0.02 0.02 Stress echo Prox LAD 90 CABG
67 Female UC 1.59 1.59 Cath Second diagonal 80 PCI
67 Male UC d 1.63 Stress echo d d Ischemic stroke
68 Male UC d 0.05 Stress echo d d d
71 Male UC 0.00 0.00 Stress echo Prox LAD 90 CABG
cath ¼ catheterization; circ ¼ circumﬂex coronary artery; echo ¼ echocardiography; LAD ¼ left anterior descending coronary artery; mid ¼ middle; prox ¼ proximal; RCA ¼ right coronary artery;
UC ¼ usual care; other abbreviations as in Tables 1 and 2.
Table 5. Study Outco
Primary outcome
Composite*
Revascularizationy
Hospital readmissio
Recurrent cardiac te
Secondary outcome
Index visit length o
Safety eventsy
Death (all cause)
ACS after discharge
Stress testing adver
Values are n (%) or media
Abbreviations as in Tab
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792revascularization. From 1 vantage point, it appears
that some OU CMR participants avoided revascu-
larization without compromising clinical outcomes.
From another perspective, the patients receiving
revascularization (Table 5) all appear to have had
critical stenoses justifying intervention. It is un-
known whether patients with similar coronary
phenotypes were in the OU CMR group, but the
randomized design makes that likely. One inter-
pretation is that in patients with symptoms attrib-
uted to unstable angina, stenotic vessels thought to
be the cause of the patients’ symptoms
may not actually cause inducible ischemia asmes and Safety Events Through 90 Days
Usual Care
(n [ 53)
OU CMR
(n [ 52) p Value
20 (38) 7 (13) 0.004
8 (15) 1 (2) 0.031
n* 12 (23) 4 (8) 0.033
sting* 9 (17) 2 (4) 0.028
f stay, hz 26.3 (22.7–44.8) 21.1 (14.8–25.2) <0.001
0 (0) 0 (0) d
3 (6) 0 (0) 0.24
se events 0 (0) 0 (0) d
n (interquartile range). *Chi-squared test. yFisher exact test. zKruskal-Wallis test.
les 1 and 2.measured by stress CMR. In these circumstances,
appropriateness criteria would support a trial of
medical therapy in some patients with single-vessel
or 2-vessel disease and low-risk ﬁndings on
noninvasive testing (21).
A similar and related ﬁnding is the management
of patients with small troponin elevations. Patients
with elevated troponin values are often referred for
revascularization because of a recognized beneﬁt of
an early invasive strategy in patients with non–
ST-segment elevation ACS, with the largest beneﬁt
observed in patients with elevated serum troponin
levels (14). Recently, troponin assays have become
more sensitive, and MI has been redeﬁned to
include patients with smaller elevations in troponin
(18). It remains unclear whether data supporting an
early invasive strategy in “troponin-positive” patients
extends to these lower-grade troponin elevations.
Mills et al. (22) reported the impact of more
sensitive troponin assays on mortality. In the 2 time
periods during which low-grade elevations were
blinded or revealed to care providers, patients
beneﬁted from improved outcomes when the low-
grade elevations were revealed. However, the main
beneﬁt from the lower troponin threshold appeared
to be derived from more aggressive medical therapy,
with no signiﬁcant difference in revascularization
rates. In our trial, 5 participants had peak troponin
values higher than the upper limit of normal
and <1.0 ng/ml before any coronary intervention.
Of these “small” elevations, 3 underwent vasodi-
lator CMR or stress echocardiography as the ﬁrst
test, leading to uneventful discharge. These very
Figure 2. Cumulative Incidence Curves
Cumulative incidence curves demonstrate an early reduction in
composite events that continued through 90 days in the obser-
vation unit cardiac magnetic resonance (OUCMR) group compared
with the usual care group.
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793preliminary ﬁndings suggest that highly accurate
noninvasive testing may aid in the selection of pa-
tients for invasive testing and revascularization.
Study limitations. The strengths of this analysis
relate to the randomized design, high adherence to
the OU CMR pathway, and rigorous data collection
and follow-up procedures. In trade-off, our work
had limitations. Because of the single-center design,
these ﬁndings will need to be replicated across
multiple centers to ensure external validity of the
ﬁndings. We did not adjudicate the appropriateness
of revascularization and therefore cannot comment
on whether the reductions in revascularization
would have been classiﬁed as appropriate. However,
we submit that the absence of events in the short
term makes it unlikely that patients in need of
life-sustaining revascularization were deprived of
this intervention. Longer term follow-up is beingconducted to determine if revascularizations were
required after the 90-day period; our prior investi-
gation did not reveal an increase in post-discharge
events through 1 year in a similar OU CMR
group (8). It is possible that our ﬁndings relate to an
imbalance in ischemic cardiac events among the
study groups despite our randomized design. We
believe that this is less likely, because predictors of
adverse cardiac events such as the TIMI risk score
and initial electrocardiographic ﬁndings did not
differ among groups and because efﬁciency gains
have now been observed in both of our studies.
Additionally, incomplete blinding could have
changed patients’ or care providers’ behavior, despite
our attempts to prevent this source of bias. Finally,
we cannot speciﬁcally comment on the safety of the
2 groups, given that events after discharge were rare.
Given that most patients in both groups underwent
serial cardiac biomarker assessments and objective
cardiac testing, we believe that it is unlikely that the
safety of the 2 approaches differs.CONCLUS IONS
In this single-center trial, management of
intermediate-risk patients with possible ACS in an
OU with stress CMR reduced coronary artery
revascularization, hospital readmissions, and recur-
rent cardiac testing, without an increase in post-
discharge ACS at 90 days.Reprint requests and correspondence: Dr. Chadwick D.
Miller, Wake Forest School of Medicine, Department of
Emergency Medicine, Medical Center Boulevard,
Winston-Salem, North Carolina 27157. E-mail: cmiller@
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